- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Léčba PCSK9 inhibitory v praxPublication without faculty affiliation
- Indication of PCSK9 inhibitors in the expert view of the CSAT2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Ezetimibe and combination of lipid lowering medications: what is their role in the era of PCSK9 inhibitors?2017 | First Faculty of Medicine
- PCSK9 inhibitors in light of recent data2016 | First Faculty of Medicine
- PCSK9 inhibitory: milník v léčbě dyslipidemií2016 | First Faculty of Medicine
- Severe familial hypercholesterolemia treatment2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology2022 | First Faculty of Medicine
- News in cardiovascular prevention: from guidelines to novel treatment options2015 | First Faculty of Medicine
- New possibilities of dyslipidemiaa therapy in patients with familial hypercholesterolemia in secondary prevention - change in reimbursement for PCSK9 inhibitors2021 | First Faculty of Medicine
- Coronary atherosclerosis regression - theory, facts and clinical relevance2016 | Faculty of Medicine in Hradec Králové
- News in the treatment of dyslipidaemia2019 | First Faculty of Medicine
- Current and future trends in the treatment of dyslipidemias2019 | First Faculty of Medicine
- The treatment of hypercholesterolemia by PCSK9 inhibitors2014 | Faculty of Medicine in Hradec Králové
- Low concentration of plasma cholesterol and type 2. diabetes mellitus2021 | First Faculty of Medicine
- How deep is LDL cholesterol fall?2014 | First Faculty of Medicine
- Repatha - evolocumab, first in Europe registered inhibitors PCSK2015 | First Faculty of Medicine
- Why do we fail when treating dyslipidemia? +12018 | First Faculty of Medicine
- A near future of treatment of dyslipidemia in type 2 diabetics2016 | First Faculty of Medicine
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment2016 | First Faculty of Medicine
- News in lipid lowering treatment2014 | First Faculty of Medicine
- New options in diagnostics and treatment of familial hypercholesterolemia2018 | First Faculty of Medicine
- Fixed-combination of rosuvastatin with ezetimibe in the treatment of secondary prevention patient2018 | First Faculty of Medicine
- News about familial hypercholesterolaemia for cardiologists2019 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Current and future possibilities to influence dyslipidemia2016 | First Faculty of Medicine
- Aktuality ze světa inhibice PCSK92019 | First Faculty of Medicine
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial2019 | First Faculty of Medicine